Severe hypocalcemia and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome under deferasirox therapy for myelodysplasic syndrome

2011 ◽  
Vol 87 (2) ◽  
pp. 233-233 ◽  
Author(s):  
Benoit Ben Said ◽  
A. Rozieres ◽  
Olivier Martin ◽  
Jean-Francois Nicolas ◽  
Frederic Berard
Keyword(s):  
Drug Reaction ◽  
Dress Syndrome ◽  
Systemic Symptoms

scholarly journals Raltegravir-associated Drug-Reaction With Eosinophilia and Systemic Symptoms Syndrome in a Pediatric Patient Without Characteristic Human Leukocyte Antigen B*57:01 or B*53:01 alleles

2020 ◽  
Author(s):  
Sanya J Thomas ◽  
Jacob T Kilgore ◽  
Bradford A Becken ◽  
Coleen K Cunningham ◽  
Amelia B Thompson
Keyword(s):  
Drug Reaction ◽  
Human Leukocyte Antigen ◽  
Human Leukocyte ◽  
African American Female ◽  
Dress Syndrome ◽  
Leukocyte Antigen ◽  
Antigen B ◽  
Immunodeficiency Virus ◽  
Perinatally Acquired ◽  
Systemic Symptoms

Abstract We present the first published case of raltegravir-associated drug-reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a child without characteristic human leukocyte antigen haplotypes HLA-B*57:01 or HLA-B*53:01. A 4-year-old African American female with perinatally acquired human immunodeficiency virus infection was hospitalized for DRESS after starting a raltegravir-based antiretroviral regimen.

scholarly journals Erosive cheilitis as an early manifestation in DRESS syndrome

2021 ◽  
Author(s):  
wahbi ben salha ◽  
eya moussaoui ◽  
lamia oualha ◽  
Jihed Anoun ◽  
Nabiha Douki
Keyword(s):  
Uric Acid ◽  
Drug Reaction ◽  
Adverse Reactions ◽  
Dress Syndrome ◽  
Mucosal Involvement ◽  
Severe Cutaneous Adverse Reactions ◽  
Lowering Drug ◽  
Systemic Symptoms ◽  
Cutaneous Adverse Reactions ◽  
Early Manifestation

Drug reaction with eosinophilia and systemic symptoms (DRESS) is part of Severe cutaneous adverse reactions. Allopurinol, an uric acid-lowering drug, had been incriminated in several cases of Allopurinol-induced Dress syndrome.Through this paper, we present a case of Allopurinol-induced DRESS syndrome with initial oral mucosal involvement.

Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine

2020 ◽  
pp. ejhpharm-2019-002149
Author(s):  
Beatriz Torroba Sanz ◽  
Elena Mendez Martínez ◽  
Elena Cacho Asenjo ◽  
Irene Aquerreta Gonzalez
Keyword(s):  
Drug Reaction ◽  
Dress Syndrome ◽  
Systemic Symptoms

scholarly journals Angioimmunoblastic-T-cell-lymphoma mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome

2018 ◽  
Vol 101 ◽  
pp. S23
Author(s):  
Ioanna Mangana ◽  
Reinhard Dummer ◽  
Mirjana Urosevic Maiwald ◽  
Katrin Kerl ◽  
Lars E. French ◽  
...  
Keyword(s):  
Drug Reaction ◽  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Dress Syndrome ◽  
Angioimmunoblastic T Cell Lymphoma ◽  
Systemic Symptoms

scholarly journals An investigation into the avoidability of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Mohammed Ibn-Mas’ud Danjuma ◽  
Lina Mohammad Ahmad Naseralallah ◽  
Bodoor AbouJabal ◽  
Mouhand Faisal Mohamed ◽  
Ibrahim Y. Abubeker ◽  
...  
Keyword(s):  
Drug Reaction ◽  
Clinical Presentation ◽  
Intraclass Correlation ◽  
Significant Proportion ◽  
Dress Syndrome ◽  
Study Population ◽  
The Mean ◽  
Systemic Symptoms ◽  
Larger Sample

AbstractDrug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rising morbidity amongst hospitalized patients. Whilst clinical protocols for the management of individual DRESS cases have been well established, determination of potential prevention of these cases by utilizing novel “avoidability” tools has remained unexplored. This retrospective study reviewed records of patients who presented to the emergency department of Weill Cornell Medicine-affiliated Hamad General Hospital, Doha Qatar with suspected DRESS syndrome. These cases were independently adjudicated (utilizing the RegiSCAR, and JSCAR tools) as DRESS-drug pairs by a team of two clinical pharmacists and two General Physicians. They were then rated for potential avoidability with the Liverpool adverse drug reactions avoidability tool (LAAT) by the same team of raters. A total of 16 patients satisfied RegiSCAR criteria for DRESS syndrome. The mean age of the study population was 41.5 years (SD ± 13.3). The study population was predominantly male (n = 12; [75%]). The median latent period from drug ingestion to clinical presentation was 14 days (interquartile range [IQR] 6.5, 29). The median RegiSCAR and J-SCAR scores were 6 (IQR 5, 6.8), 5 (IQR 4, 5.8) respectively. Utilizing the LAAT, about 60% of the DRESS syndrome-drug pairs were rated as “avoidable” (“probable” or “definite”). The overall Krippendorf’s alpha with the LAAT was 0.81 (SE 0.10, CI 0.59–1.00); with an intraclass correlation coefficient (ICC) of 0.90 (CI 0.77, 0.96.). In a randomly selected cohort of DRESS syndrome-drug pairs, a significant proportion was potentially avoidable (“possibly” and “definitely”) utilizing the LAAT. This will need validation by larger sample-sized prospective studies utilizing the updated LAAT proposed by this study.

Rate of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with raltegravir and role of the HLA-B*53

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
M Lefebvre ◽  
A Walencik ◽  
C Allavena ◽  
E Billaud ◽  
A Kassi ◽  
...  
Keyword(s):  
Drug Reaction ◽  
Dress Syndrome ◽  
Systemic Symptoms
Sign in / Sign up

Export Citation Format

Share Document